Delayed graft function in kidney transplantation: a review of contemporary challenges and updates

Delayed graft function (DGF) is commonly defined as dialysis needed within one week post-transplant. DGF is a common early post-transplant complication associated with detrimental outcomes. To overcome the shortage of donors, the criteria for selecting deceased donors have been liberalized. Increased associated risks with DGF-associated transplants, including donors with acute kidney injury, older age donors, prolonged cold ischemia time, and out-of-sequence kidneys, have become increasingly prevalent. There is currently no Food and Drug Administration (FDA)-approved DGF-related therapy. Previous strategies implemented to prevent adverse outcomes related to DGF include donor-recipient matching, kidney offers for preemptive transplant with a high risk for DGF, machine perfusion, and more. In this manuscript, we discuss pertinent updates regarding DGF in policy, epidemiology, diagnostics, and therapeutics to supplement the literature and to foster ongoing research.

Authors

Institutions

Publication Details

Journal
Journal of Nephrology
Published
2026-02-27
DOI
https://doi.org/10.1093/joneph/aajaf044
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Delayed graft function in kidney transplantation: a review of contemporary challenges and updates

Kurtis J. Swanson, Sandesh Raman Parajuli, Kian Djamali
Journal of Nephrology
Renal Transplantation Outcomes and Treatments
article

Delayed graft function in kidney transplantation: a review of contemporary challenges and updates

Kurtis J. Swanson, Sandesh Raman Parajuli, Kian Djamali
article en

Abstract

Delayed graft function (DGF) is commonly defined as dialysis needed within one week post-transplant. DGF is a common early post-transplant complication associated with detrimental outcomes. To overcome the shortage of donors, the criteria for selecting deceased donors have been liberalized. Increased associated risks with DGF-associated transplants, including donors with acute kidney injury, older age donors, prolonged cold ischemia time, and out-of-sequence kidneys, have become increasingly prevalent. There is currently no Food and Drug Administration (FDA)-approved DGF-related therapy. Previous strategies implemented to prevent adverse outcomes related to DGF include donor-recipient matching, kidney offers for preemptive transplant with a high risk for DGF, machine perfusion, and more. In this manuscript, we discuss pertinent updates regarding DGF in policy, epidemiology, diagnostics, and therapeutics to supplement the literature and to foster ongoing research.

Journal of Nephrology
University of Wisconsin–Madison (US), University of Wisconsin Health (US), Wisconsin Division of Public Health (US)
Good health and well-being
Openalex Percentile: Top 42%
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Delayed graft function in kidney transplantation: a review of contemporary challenges and updates — Kurtis J. Swanson, Sandesh Raman Parajuli, et al. · Journal of Nephrology (2026) | TGRS Research Map | TGRS